Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
5 stopped studies mapped to Dedifferentiated Liposarcoma and descendants · 100% state a reason
Over the 5 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05496569 | TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | Phase 2 | terminated | Aug 11, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05580588 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or… | Phase 2 | terminated | Oct 14, 2022 | Shanghai Pharma Biotherapeutics USA Inc. | Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less… | Safety / toxicity |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | Phase 3 | terminated | Jul 28, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | Phase 1 | terminated | Jul 27, 2018 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate further development of the program. | Sponsor / business decision |
| NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced… | Phase 2 | withdrawn | Sep 2, 2009 | Infinity Pharmaceuticals, Inc. | Company decision not to start the study | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 21, 2025source: clinicaltrials